AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22015542 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART treatment
Number of subjects: 102
Study 22015542 — intervention group
Group type: COMPARATOR
Intervention: UC treatment
Number of subjects: 102
Study 20439575 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d subcutaneously)
Number of subjects: 96
Study 20439575 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d)
Number of subjects: 96
Study 20439575 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (2 mg/d) with testosterone (250 mg/wk intramuscularly)
Number of subjects: 96
Study 20439575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17427828 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III one‐step self‐etch adhesive (Dentsply/Caulk)
Number of subjects: 30
Study 17427828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT total‐etch adhesive (Dentsply/Caulk)
Number of subjects: 30
Study 17427828 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐Bond one‐step self‐etch adhesive (Heraeus Kulzer)
Number of subjects: 30
Study 17427828 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond two‐step self‐etch adhesive (Kuraray Medical)
Number of subjects: 30
Study 15730611 — intervention group
Group type: EXPERIMENTAL
Intervention: Apex auscultation
Number of subjects: 56
Study 15730611 — intervention group
Group type: COMPARATOR
Intervention: Carotid pulse palpation
Number of subjects: 56
Study 15730611 — intervention group
Group type: COMPARATOR
Intervention: Brachial pulse palpation
Number of subjects: 56
Study 15730611 — intervention group
Group type: COMPARATOR
Intervention: Femoral pulse palpation
Number of subjects: 56
Study 11929643 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 EE
Number of subjects: 48
Study 11929643 — intervention group
Group type: COMPARATOR
Intervention: 30 EE
Number of subjects: 48
Study 9928553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 5 years
Number of subjects: 0
Study 9928553 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 0
Study 9928553 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0
Study 9928553 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 9928553 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0
Study 9928553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine manipulation (future trials)
Number of subjects: 0
Study 7637824 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen breathing for 15‐20 min before radiotherapy
Number of subjects: 47
Study 7637824 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 47
Study 2692891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 150
Study 2692891 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 150
Study 625655 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (Voltaren) 75 mg daily from week 4
Number of subjects: 40
Study 625655 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (Proxen) 500 mg daily from week 4
Number of subjects: 40
Study 30442052 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring dietary advice (Tele‐GDM group)
Number of subjects: 57
Study 30442052 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional follow-up)
Number of subjects: 57
Study 28259854 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention starting at 2 weeks after randomisation
Number of subjects: 80
Study 28259854 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy starting at 6 weeks after randomisation
Number of subjects: 80
Study 25760742 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0
Study 25760742 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study 24055681 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN‐CBT
Number of subjects: 81
Study 24055681 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN‐Progressive Muscle Relaxation therapy (PMR)
Number of subjects: 81
Study 24055681 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (PLC)‐CBT
Number of subjects: 81
Study 24055681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)‐PMR
Number of subjects: 81
Study 20739054 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg once daily)
Number of subjects: 197
Study 20739054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 19169289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 18 mg
Number of subjects: 61
Study 19169289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 12 mg
Number of subjects: 61
Study 19169289 — intervention group
Group type: COMPARATOR
Intervention: Daily filgrastim (10 microg/kg for < or =7 days)
Number of subjects: 61
Study 19169289 — intervention group
Group type: COMPARATOR
Intervention: Daily filgrastim (5 microg/kg/day for < or =14 days)
Number of subjects: 61
Study 17482099 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 17482099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 0
Study 17482099 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis strategies for CIN
Number of subjects: 0
Study 15480402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate infusion
Number of subjects: 23
Study 15480402 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional immobilization methods)
Number of subjects: 23
Study 11296091 — intervention group
Group type: EXPERIMENTAL
Intervention: SR141716 (90 mg)
Number of subjects: 63
Study 11296091 — intervention group
Group type: EXPERIMENTAL
Intervention: SR141716 (1, 3, 10, 30, and 90 mg)
Number of subjects: 63
Study 11296091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9416985 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 9903
Study 9416985 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine sustained release
Number of subjects: 9903
Study 9416985 — intervention group
Group type: COMPARATOR
Intervention: Other active drugs
Number of subjects: 9903
Study 9416985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9903
Study 8293730 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 53
Study 8293730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior occurrence of posttreatment nervousness
Number of subjects: 53
Study 8293730 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety before the 1st infusion
Number of subjects: 53
Study 3323290 — intervention group
Group type: EXPERIMENTAL
Intervention: iv calcium infusion
Number of subjects: 6
Study 3323290 — intervention group
Group type: EXPERIMENTAL
Intervention: oral diltiazem administration for one week
Number of subjects: 6
Study 3323290 — intervention group
Group type: EXPERIMENTAL
Intervention: acute iv diltiazem infusion
Number of subjects: 6
Study 3323290 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-TRH stimulation
Number of subjects: 6
Study 3323290 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium and diltiazem treatments
Number of subjects: 6
Study 31501078 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 120
Study 31501078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball squeezing
Number of subjects: 120
Study 31501078 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 120
Study 31501078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 28422576 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (BCBT)
Number of subjects: 152
Study 28422576 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 152
Study 27138028 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone (5, 25, or 50mg)
Number of subjects: 38
Study 27138028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24144628 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-derived balanced 6% HES 130/0.42 with 500 mL of Ringer's lactate (HESPRL)
Number of subjects: 80
Study 24144628 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-derived balanced 6% HES 130/0.42 (HESP)
Number of subjects: 80
Study 24144628 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy maize-derived balanced 6% HES 130/0.4 with 500 mL of Ringer's lactate (HESMRL)
Number of subjects: 80
Study 24144628 — intervention group
Group type: EXPERIMENTAL
Intervention: Waxy maize-derived balanced 6% HES 130/0.4 (HESM)
Number of subjects: 80
Study 24144628 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 22234633 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab
Number of subjects: 480
Study 22234633 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab
Number of subjects: 480
Study 20484550 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (daidzein)
Number of subjects: 1293
Study 20484550 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (genistein)
Number of subjects: 1293
Study 20484550 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC (n-3) fatty acids (eicosapentaenoic acid - EPA)
Number of subjects: 1293
Study 20484550 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC (n-3) fatty acids (docosapentaenoic acid - DPA)
Number of subjects: 1293
Study 18755353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 34
Study 18755353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16798053 — intervention group
Group type: EXPERIMENTAL
Intervention: GAITRite gait analysis system
Number of subjects: 13
Study 14743119 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 12-15 ml of ropivacaine 0.75% and fentanyl 5 microg/ml followed by light general anesthesia and postoperative epidural analgesia with ropivacaine 0.2% and fentanyl 2 mg/ml
Number of subjects: 25
Study 14743119 — intervention group
Group type: COMPARATOR
Intervention: Inhalatory or intravenous general anesthesia and intravenous tramadol postoperative analgesia
Number of subjects: 25
Study 14743119 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-GEN group
Number of subjects: 25
Study 11078493 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR (200 mg/d)
Number of subjects: 0
Study 11078493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8749970 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during venipuncture
Number of subjects: 130
Study 8749970 — intervention group
Group type: COMPARATOR
Intervention: Parents absent during venipuncture
Number of subjects: 130
Study 8749970 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional performing venipuncture
Number of subjects: 130
Study 1532970 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 52
Study 1532970 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 52
Study 1532970 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients selected for late enlargement (n = 19)
Number of subjects: 52
Study 3926862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 13
Study 3926862 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 13
Study 29325593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Changes programme (12-week group-based training)
Number of subjects: 237
Study 29325593 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 237
Study 27049107 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg sodium hyaluronate plus saline solution
Number of subjects: 48
Study 27049107 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 48
Study 24885889 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach (pain neuroscience education followed by cognition-targeted motor control training)
Number of subjects: 120
Study 24885889 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy
Number of subjects: 120
Study 24885889 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern neuroscience approach
Number of subjects: 120
Study 22664486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with an implantable defibrillator (CRT-D)
Number of subjects: 80
Study 22664486 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) assessment using the Minnesota Living with Heart Failure questionnaire
Number of subjects: 80
Study 20488825 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 85
Study 20488825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 18759963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anticoagulation with unfractioned heparin (UFH) and tirofiban
Number of subjects: 40
Study 18759963 — intervention group
Group type: COMPARATOR
Intervention: Unfractioned heparin (UFH)
Number of subjects: 40
Study 16157415 — intervention group
Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating fruits
Number of subjects: 188
Study 16157415 — intervention group
Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating vegetables
Number of subjects: 188
Study 16157415 — intervention group
Group type: EXPERIMENTAL
Intervention: Token reinforcement for eating fruits and vegetables
Number of subjects: 188
Study 12149235 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF‐mobilized peripheral blood hematopoietic stem cell transplantation (PBHSCT)
Number of subjects: 51
Study 12149235 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 51
Study 9952152 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (100 microg/kg) administered as a rapid intravenous bolus dose every 4-6 hours
Number of subjects: 60
Study 7593731 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 to 450 mg daily
Number of subjects: 0
Study 2406656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal interventions provided by nurse‐midwives and nurses under their supervision
Number of subjects: 1458
Study 2406656 — intervention group
Group type: COMPARATOR
Intervention: Standard high‐risk prenatal care provided by obstetricians
Number of subjects: 1458
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated colonoscopy 3 months after polypectomy in 80 patients
Number of subjects: 629
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated colorectal examinations every 6 months for patients with sessile villous adenomas, carcinoma in situ, and mucosal carcinoma
Number of subjects: 629
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated colorectal examinations every 6 months for patients with stalked polyps
Number of subjects: 629
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy within 3 months of radical surgery for colorectal cancer
Number of subjects: 629
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 629
Study 6275495 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 629
Study 30452422 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (33 mg/kg/day)
Number of subjects: 17
Study 30452422 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (67 mg/kg/day)
Number of subjects: 17
Study 30452422 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg/kg/day)
Number of subjects: 17
Study 30452422 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (all doses)
Number of subjects: 17
Study 30452422 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (after 7 days of dosing)
Number of subjects: 17
Study 28840637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg
Number of subjects: 74
Study 28840637 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 74
Study 26901913 — intervention group
Group type: EXPERIMENTAL
Intervention: St‐Jude Trifecta stented prosthesis
Number of subjects: 40
Study 26901913 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Freestyle stentless prosthesis
Number of subjects: 40
Study 23329538 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium plasma-sprayed cup with hydroxyapatite coating
Number of subjects: 42
Study 23329538 — intervention group
Group type: COMPARATOR
Intervention: Titanium plasma-sprayed cup without hydroxyapatite coating
Number of subjects: 42
Study 23329538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without hydroxyapatite coating)
Number of subjects: 42
Study 21539882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of PCV
Number of subjects: 8
Study 21539882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of PCV
Number of subjects: 8
Study 21539882 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of PCV
Number of subjects: 8
Study 21539882 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPS booster at 12 months
Number of subjects: 8
Study 21539882 — intervention group
Group type: EXPERIMENTAL
Intervention: mPPS at 17 months
Number of subjects: 8
Study 21539882 — intervention group
Group type: COMPARATOR
Intervention: 0 doses of PCV
Number of subjects: 8
Study 19388864 — intervention group
Group type: EXPERIMENTAL
Intervention: D&G combination (3 g)
Number of subjects: 100
Study 19388864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 capsules)
Number of subjects: 100
Study 19388864 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label D&G (1.5 g/day for 6 months)
Number of subjects: 100
Study 17924300 — intervention group
Group type: EXPERIMENTAL
Intervention: STW 5
Number of subjects: 961
Study 17924300 — intervention group
Group type: COMPARATOR
Intervention: MCP
Number of subjects: 961
Study 15303765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 47
Study 15303765 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 47
Study 11319645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (41.4+/‐1.4 en% fat)
Number of subjects: 10
Study 11319645 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (17+/‐0.9 en% of fat)
Number of subjects: 10
Study 9713664 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician counseling plus follow-up
Number of subjects: 24
Study 9713664 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 7994025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN)
Number of subjects: 513
Study 7994025 — intervention group
Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 513
Study 7994025 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 513
Study 2898268 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 26830A, 200 mg daily for two weeks then 400 mg daily for 18 weeks
Number of subjects: 40
Study 2898268 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 weeks
Number of subjects: 40
Study 30347431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 20 mg
Number of subjects: 24
Study 30347431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 100 mg
Number of subjects: 24
Study 30347431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 450 mg
Number of subjects: 24
Study 30347431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 80 mg once daily for 14 days
Number of subjects: 24
Study 30347431 — intervention group
Group type: EXPERIMENTAL
Intervention: Verubecestat (MK-8931) 150 mg once daily for 14 days
Number of subjects: 24
Study 30347431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28399935 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy with VR training
Number of subjects: 224
Study 28399935 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 224
Study 25794299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methylphenidate (up to 5mg×3) for 4 weeks
Number of subjects: 51
Study 25794299 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal dose methylphenidate (up to 20mg×3) for 4 weeks
Number of subjects: 51
Study 25794299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (60mg/day spread over three doses)
Number of subjects: 51
Study 25794299 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication for 4 weeks)
Number of subjects: 51
Study 23211647 — intervention group
Group type: EXPERIMENTAL
Intervention: FVFP supplement (fruit plus vegetable concentrate, fish oil and probiotics)
Number of subjects: 192
Study 23211647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 23211647 — intervention group
Group type: EXPERIMENTAL
Intervention: FVFP supplement
Number of subjects: 192
Study 21477682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol (200 mg mifepristone and 800 mcg buccal misoprostol 24 h later)
Number of subjects: 400
Study 21477682 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-only (800 mcg buccal misoprostol 24 h apart)
Number of subjects: 400
Study 21477682 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-only
Number of subjects: 400
Study 21477682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone+misoprostol
Number of subjects: 400
Study 20133265 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 86
Study 16421418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Number of subjects: 344
Study 16421418 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Anthracycline-Based Chemotherapy (SD-CT)
Number of subjects: 344
Study 15204429 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl loading
Number of subjects: 10
Study 15204429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10